Spinal Muscular Atrophy Patients Treated with Onasemnogene Abeparvovec through a Managed Access Program: A Case Series

被引：0
|
作者：
Schultz, M.
Richardson, R.
Patterson, K.
机构：
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
Neuromuscular Disorders; Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
197
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [11] Onasemnogene abeparvovec for spinal muscular atrophy: The costlier drug ever
    Mahajan, Rajiv
    INTERNATIONAL JOURNAL OF APPLIED AND BASIC MEDICAL RESEARCH, 2019, 9 (03) : 127 - 128
  • [12] Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec
    Beri, Nidhi
    Kapoor, Lekha
    Parashar, Deepak
    Mundada, Vivek
    ARCHIVES OF DISEASE IN CHILDHOOD, 2023, 108 (10) : 866 - 867
  • [13] Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy
    Mcmillan, Hugh J.
    Baranello, Giovanni
    Farrar, Michelle A.
    Zaidman, Craig M.
    Moreno, Teresa
    De Waele, Liesbeth
    Jong, Yuh-Jyh
    Laugel, Vincent
    Quijano-Roy, Susana
    Mercuri, Eugenio
    Chien, Yin-Hsiu
    Straub, Volker
    Darras, Basil T.
    Seibert, Julia
    Bernardo Escudero, Roberto
    Alecu, Iulian
    Freischlaeger, Frank
    Muntoni, Francesco
    NEUROLOGY, 2025, 104 (02)
  • [14] An evaluation of onasemnogene abeparvovec for spinal muscular atrophy (SMN1)
    Waldrop, Megan A.
    Connolly, Anne M.
    Mendell, Jerry R.
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (7-10): : 199 - 204
  • [15] Onasemnogene-abeparvovec administration to premature infants with spinal muscular atrophy
    Brown, Stephen M.
    Ajjarapu, Aparna S.
    Ramachandra, Divya
    Blasco-Perez, Laura
    Costa-Roger, Mar
    Tizzano, Eduardo F.
    Sumner, Charlotte J.
    Mathews, Katherine D.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (11): : 3042 - 3046
  • [16] Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy
    D'Silva, Arlene M.
    Holland, Sandra
    Kariyawasam, Didu
    Herbert, Karen
    Barclay, Peter
    Cairns, Anita
    MacLennan, Suzanna C.
    Ryan, Monique M.
    Sampaio, Hugo
    Smith, Nicholas
    Woodcock, Ian R.
    Yiu, Eppie M.
    Alexander, Ian E.
    Farrar, Michelle A.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2022, 9 (03): : 339 - 350
  • [17] SOCIETAL COSTS OF SPINAL MUSCULAR ATROPHY TYPE 1 FOR PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC OR NUSINERSEN IN THE UNITED KINGDOM
    Kleintjens, J.
    Patel, A.
    van Keep, M.
    Srivastava, K.
    McHale, P.
    Affinito, S.
    Bischof, M.
    VALUE IN HEALTH, 2024, 27 (06) : S135 - S135
  • [18] Outcomes of Children Treated With Nusinersen/Onasemnogene Abeparvovec for Pediatric Spinal Muscular Atrophy Type 1
    Chacko, A.
    Sly, P. D.
    Gauld, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [19] Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec
    Matesanz, Susan E.
    Curry, Candace
    Gross, Brianna
    Rubin, Adam I.
    Linn, Rebecca
    Yum, Sabrina W.
    Kichula, Elizabeth A.
    JOURNAL OF CHILD NEUROLOGY, 2020, 35 (11) : 717 - 723
  • [20] Bulbar function for patients with spinal muscular atrophy type 1 following onasemnogene abeparvovec
    McGrattan, K.
    Shell, R.
    Hurst-Davis, R.
    Young, S. Dunaway
    O'Brien, E.
    Lavrov, A.
    Wallach, S.
    LaMarca, N.
    Reyna, S.
    Darras, B.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S85 - S85
12345